Success Metrics

Clinical Success Rate
25.0%

Based on 2 completed trials

Completion Rate
25%(2/8)
Active Trials
0(0%)
Results Posted
350%(7 trials)
Terminated
6(75%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_3
4
50%

Phase Distribution

0

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

2 of 8 finished

Non-Completion Rate

75.0%

6 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(2)
Terminated(6)

Detailed Status

Terminated6
Completed2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
25.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (50.0%)
Phase 34 (50.0%)

Trials by Status

completed225%
terminated675%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_3

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT03955146
terminatedphase_2

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT02606136
terminatedphase_3

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

NCT04632940
terminatedphase_3

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT04419558
terminatedphase_3

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

NCT04371666
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03955146Phase 3

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Terminated
NCT02606136Phase 2

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Terminated
NCT04632940Phase 3

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Terminated
NCT04419558Phase 3

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Terminated
NCT04371666Phase 3

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Terminated
NCT04432298Phase 2

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

Terminated
NCT05262309Phase 2

An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

Completed
NCT01890265Phase 2

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8